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Abstract Long-chain saturated fatty acids are cytotoxic to
pancreatic L-cells while shorter-chain saturated and long-chain
unsaturated molecules are better tolerated. Mono-unsaturated
fatty acids are not, however, inert since they inhibit the pro-
apoptotic e¡ects of saturated molecules. In the present work we
show that the mono-unsaturates palmitoleate (C16:1) or oleate
(C18:1) also cause marked inhibition of apoptosis induced by
exposure of clonal BRIN-BD11 L-cells to serum withdrawal or
a combination of interleukin-1L plus interferon-Q. This response
was dose-dependent and not accompanied by changes in NO
formation. Taken together, the results suggest that mono-unsat-
urated fatty acids regulate a distal step common to several ap-
optotic pathways in pancreatic L-cells.
- 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Loss of pancreatic L-cells by increased apoptosis is now
recognised as a feature common to both type 1 and type 2
diabetes [1,2], although the mechanisms responsible are likely
to be di¡erent in each case. In type I diabetes, an autoimmune
reaction is mounted against speci¢c pancreatic islet antigens
leading to in¢ltration of islets by macrophages and T-cells [3].
These cells then secrete cytokines (such as interleukin-1L (IL-
1L), interferon-Q (IFNQ) and tumour necrosis factor-K
(TNFK)) which induce the transcription of nitric oxide syn-
thase (iNOS) and cause the production of NO in the L-cells
[3^5]. Moderate elevation of NO then results in the activation
of apoptosis [6] although higher levels may also cause necrotic
death [7]. By contrast, in type 2 diabetes, a still unde¢ned
process of ‘lipotoxicity’ is responsible for L-cell death [8].
This also results from an increase in apoptosis and it is be-
lieved that elevated circulating saturated free fatty acids
(FFA) are primarily responsible [9^11], although their e¡ects
are probably exacerbated by accompanying hyperglycaemia
[8,12,13]. Increased production of NO has been reported
upon exposure of islets to FFA [14^16] but other evidence
suggests that fatty acid-mediated L-cell toxicity is independent
of NO formation [17^19].
Despite the evidence that L-cell lipotoxicity is mediated by
circulating FFA, it has also become clear that fatty acids
di¡er markedly in their ability to promote L-cell apoptosis.
Long-chain saturated molecules appear to be the most cyto-
toxic while the equivalent mono-unsaturates are ine¡ective
and have even been shown to protect L-cells against the tox-
icity of saturated fatty acids [18,20^24]. The reasons for this
di¡erence have not been established although they could re-
late to di¡erential partitioning of the various species into neu-
tral lipids [18,25]. An attractive alternative hypothesis is that
the di¡erences may relate to the ability of unsaturated mole-
cules to preferentially stabilise mitochondria, thereby minimis-
ing cytochrome c release and caspase activation [26,27]. In
support of this, Maedler et al. [20] have recently shown that
unsaturated fatty acids can attenuate mitochondrial cyto-
chrome c release in L-cells.
If this hypothesis is valid and mitochondrial stabilisation is
important for the protective e¡ects of unsaturated fatty acids,
then it might be expected that these molecules would also
improve the viability of pancreatic L-cells exposed to other
cytotoxic stimuli (in addition to saturated fatty acids). This
is because the mitochondrial events represent a common distal
component involved in the activation of apoptosis by multiple
stimuli [28]. However, to date, the e¡ects of unsaturated fatty
acids on other inducers of apoptosis have not been systemati-
cally tested although, in one study in insulin-secreting INS-1
cells, it was observed that oleate enhanced the response to IL-
1L [29]. Therefore, in the present work, we have examined the
e¡ects of selected saturated and unsaturated fatty acids on
pancreatic L-cell viability. In particular, we have investigated
whether long-chain mono-unsaturates di¡erentially regulate
apoptosis induced by either lipid (saturated fatty acids) or
non-lipid (serum withdrawal; cytokines) stimuli.
2. Materials and methods
2.1. Materials
All fatty acids except palmitoleate (from ICN) were purchased from
Sigma. Most cell culture reagents were purchased from Invitrogen,
although foetal bovine serum was from PPA Laboratories. Etomoxir
was a kind gift from Dr Greg Cooney. IL-1L and IFN-Q were pur-
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chased from Calbiochem. All other reagents were purchased from
Sigma.
2.2. Cell culture
The insulin-secreting rat L-cell line BRIN-BD11 [30] was cultured in
RPMI 1640 medium containing 11 mM glucose, 10% foetal bovine
serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 Wg/ml strep-
tomycin. Cells were cultured at 37‡C in 5% CO2 and were used in
experiments when approximately 80% con£uent.
2.3. Preparation of fatty acids and treatment of cells
Fatty acid solutions for use in cell incubations were prepared in
accordance with Jacqueminet et al. [31]. Stearate, palmitate, myristate
and octanoate were each initially dissolved in 50% ethanol by heating
to 70‡C. Oleate and palmitoleate were dissolved in 90% ethanol. The
dissolved fatty acids were then bound to albumin by mixing with a
10% fatty acid-free bovine albumin solution at 37‡C for 1 h. This
mixture was added to modi¢ed RPMI 1640 medium containing 5.5
mM glucose to give ¢nal concentrations of 0.5% ethanol and 1%
bovine serum albumin (BSA). Cells were treated with the fatty acid
mixtures plus appropriate compounds in 6 well plates seeded the
previous day with 1U105 cells/well. All control wells received vehicle
alone (0.5% ethanol and 1% BSA).
2.4. Measurement of cell death
For routine determination of cell death, vital dye staining was used.
Floating and attached cells were collected from each well, centrifuged
at 200Ug for 5 min and resuspended in 150 Wl of RPMI 1640 me-
dium. This was then mixed with 150 Wl of trypan blue (0.4% in phos-
phate-bu¡ered saline (PBS)). The numbers of live and dead cells were
counted using a haemocytometer and the percentage dead cells calcu-
lated.
In some experiments, induction of apoptosis was measured using
either annexin V-Cy3 staining or measurements of caspase activation.
2.4.1. CaspACE assay. CaspACE1 FITC-VAD-FMK In Situ
Marker (Promega) is a £uoroisothiocyanate conjugate of the cell-per-
meable caspase inhibitor VAD-FMK. Following exposure to fatty
acids, cells were harvested and resuspended in 50 Wl of PBS. 10 Wl
was removed and mixed with 10 Wl of CaspACE substrate (10 WM
¢nal concentration). Cells were incubated in the dark at 37‡C for 20
min, then centrifuged at 1000Ug for 5 min and washed in 200 Wl PBS.
The ¢nal cell pellet was resuspended in 50 Wl PBS, transferred to poly-
L-lysine-coated microscope slides and incubated at room temperature
for 5 min before viewing under a £uorescent microscope.
2.4.2. Annexin V-CY3 staining. The annexin V-Cy3 apoptosis de-
tection kit (Sigma) employs two labels: annexin-Cy3.18, a red £uo-
rescent protein, which binds to phosphatidylserine present in the outer
lea£et of the plasma membrane of cells undergoing apoptosis, and
6-carboxy£uorescein diacetate (6-CFDA). 6-CFDA measures cell via-
bility since it is hydrolysed by esterases present in living cells to pro-
duce the green £uorescent compound 6-carboxy£uorescein (6-CF).
Hence, these two labels can distinguish between live, necrotic and
apoptotic cells. BRIN-BD11 cells were washed twice then resuspended
in PBS at a density of 1U106 cells/ml. The cell suspension (50 Wl) was
added to poly-L-lysine-coated slides which were washed three times in
binding bu¡er (Sigma) before addition of 50 Wl of staining solution
(containing AnnCy3 and 6-CFDA). The cells were incubated for 10
min at room temperature in the dark, before observation under a
£uorescent microscope.
2.5. Nitrite assay
Nitrite formation was measured as an indicator of NO production.
Cells were incubated in a total volume of 1 ml with test reagents for
24 h. After this time samples of medium were removed for nitrite
measurement by the Greiss assay [6]. Samples were incubated with a
mixture (1:1 v:v) of 1% sulphanilamide and 0.1% naphthylethylenedi-
amine in 2% phosphoric acid and the optical density determined at
540 nm after colour development. Nitrite levels were determined by
reference to a standard curve constructed using sodium nitrite.
6
Fig. 1. E¡ects of fatty acids of varying chain length and degree of
saturation on cell death in BRIN-BD11 cells. A: Fatty acids (stea-
rate (Ste), palmitate (Palm), myristate (Myr), octanoate (Oct), pal-
mitoleate (PalmOle), oleate (Ole) ^ all at 0.5 mM) were bound to
albumin then introduced into the incubation medium of BRIN cells
for a period of 18 h. After this time the cells were harvested and
their viability measured by vital dye staining. *P6 0.001 relative to
untreated control cells. B: BRIN cells were exposed to 0.5 mM pal-
mitate for 18 h in the absence (control) or presence of palmitoleate
(PalmOle; 0.5 mM), oleate (Ole; 0.5 mM), myristate (Myr; 0.5
mM) or octanoate (Oct; 0.5 mM). After this time the cells were
harvested and their viability measured by vital dye staining.
*P6 0.001 relative to cells exposed to palmitate alone. C: BRIN
cells were treated with palmitate (0.5 mM) in the absence or pres-
ence of increasing concentrations of palmitoleate as shown. After in-
cubation for 18 h, the cells were harvested and their viability mea-
sured by vital dye staining. *P6 0.05, **P6 0.001 relative to
palmitate alone.
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2.6. Statistical analysis
All individual experiments were performed at least in duplicate and
were repeated on a minimum of three separate occasions. The results
were analysed by analysis of variance with Tukey’s test and were
considered signi¢cant when P6 0.05.
3. Results
3.1. Comparative e¡ects of fatty acids on L-cell viability
Initially, the e¡ects of a range of saturated and unsaturated
fatty acids were compared on the viability of BRIN-BD11
L-cells (Fig. 1). The results con¢rmed that the cells display a
marked di¡erence in sensitivity to these agents, with long-
chain saturated molecules (palmitate (C16:0) and stearate
(C18:0) up to 0.5 mM) causing a large increase in cell death
while the equivalent unsaturated molecules (palmitoleate
(C16:1) and oleate (C18:1) up to 0.5 mM) were well tolerated
(Fig. 1A). Saturated fatty acids having a chain length shorter
than C16 (e.g. myristate (C14:0) or octanoate (C8:0)) were
also ine¡ective as inducers of cell death (Fig. 1A). The cell
death caused by palmitate was largely mediated by increased
apoptosis as it was accompanied by caspase activation and
increased annexin V-Cy3 staining (2.3 P 0.6% apoptotic cells
in control vs 30.6 P 3.5% after 18 h exposure to 0.1 mM pal-
mitate; P6 0.001).
An important di¡erence between the e¡ects of shorter-chain
saturated fatty acids and long-chain mono-unsaturates was
observed when cells were exposed to combinations of FFA
(Fig. 1B). Whereas myristate and octanoate failed to in£uence
the extent of cell death caused by exposure of BRIN cells to
palmitate (or stearate ^ not shown), palmitoleate and oleate
dramatically attenuated the cytotoxic e¡ects of the saturated
molecules. This response was dose-dependent (Fig. 1C) and
concentrations of palmitoleate as low as 10 WM caused a sig-
ni¢cant improvement in viability compared to cells that were
exposed to palmitate (500 WM) in the absence of palmitoleate.
The e¡ects of palmitoleate did not result from any alteration
in the rate of cell proliferation, which was unchanged during
exposure to this fatty acid over at least 72 h (not shown).
Parallel studies established that the increase in BRIN cell
death induced by palmitate does not result from non-speci¢c
alterations in plasma membrane integrity but that a time-de-
pendent change in the transcription of still unidenti¢ed genes
is required (Welters et al., in preparation). Therefore, in the
present studies, cells were exposed to palmitoleate at di¡erent
times after the initial addition of palmitate to establish
whether the mono-unsaturated molecule can attenuate apo-
ptosis after initiation of the response to palmitate. The results
revealed (Fig. 2) that the addition of palmitoleate to the cells
up to 6 h after palmitate was still e¡ective at blocking the
increased apoptosis normally seen in response to palmitate.
3.2. E¡ects of mono-unsaturated fatty acids on L-cell death
induced by serum withdrawal or cytokine exposure
The results described above imply that palmitoleate attenu-
ates L-cell apoptosis by exerting an in£uence at a relatively
late step in the apoptotic pathway. On this basis, we consid-
ered the possibility that, if this step is also required for in-
duction of apoptosis by other agents, these might also be
sensitive to inhibition by mono-unsaturated fatty acids.
Thus, in the next series of experiments, BRIN cell death
was induced by the removal of survival factors that accom-
panies serum withdrawal. As expected, culture of BRIN cells
in medium devoid of serum led to a marked loss of viability
over 48 h (Fig. 3). However, the extent of this response was
dramatically reduced when the cells were also exposed to pal-
mitoleate (or oleate; Fig. 3) during the period of serum with-
drawal. The protective e¡ects of palmitoleate were not pre-
vented by the presence of the carnitine palmitoyltranferase-1
inhibitor etomoxir, con¢rming that mitochondrial oxidation
of the fatty acid was not required for this response.
To extend these observations further, BRIN cells were next
treated with a combination of cytokines (IL-1L (2 Wg/Wl) plus
IFNQ (1 U/Wl)). Exposure of the cells to these agents resulted
Fig. 2. Time dependence of the antagonism of palmitate-induced
toxicity by palmitoleate. BRIN cells were treated with 0.5 mM pal-
mitate (Palm) bound to 1% fatty acid-free albumin. After 0, 3 or 6 h
of incubation with palmitate, 0.25 mM palmitoleate (PO) was also
added and the culture period continued. The extent of cell death
was determined after a total of 24 h culture for all incubation con-
ditions. *P6 0.001 relative to palmitate alone.
Fig. 3. E¡ects of unsaturated fatty acids on the increase in BRIN-
BD11 cell death induced by serum withdrawal. BRIN cells were cul-
tured in RPMI 1640 medium lacking added serum but containing
fatty acid-free albumin. Palmitoleate (0.5 mM) or oleate (0.5 mM)
was included as shown and some cells also received etomoxir (0.2
mM; grey bars). Cells were harvested after culture for 48 h and
their viability determined. *P6 0.001 relative to untreated cells.
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in a large accumulation of nitrite in the culture medium, con-
sistent with the induction of iNOS (and the consequent in-
crease in NO formation) expected under these conditions (Fig.
4A). Nitrite formation was not changed by co-incubation with
palmitoleate implying that the fatty acid exerted no e¡ect on
iNOS induction. It was also established that neither palmitate
nor palmitoleate induced the production of NO from BRIN
cells (Fig. 4A). Despite its failure to inhibit cytokine-induced
NO production, treatment of BRIN cells with palmitoleate
caused a signi¢cant improvement in cell viability during ex-
posure to IL-1L and IFNQ (Fig. 4B). This suggests that the
mono-unsaturated fatty acid was able to attenuate the cyto-
toxic e¡ects of IL-1L and IFNQ by an action that lies down-
stream of NO generation.
4. Discussion
The present data demonstrate very forcibly that saturated
and unsaturated fatty acids exert markedly di¡erent e¡ects on
L-cell viability. As such, they are in accordance with recent
results obtained in primary islet cells [20,23] and show that
cultured BRIN-BD11 cells represent a suitable model for
study of the mechanisms of L-cell lipotoxicity. They also em-
phasise that the pro- and anti-apoptotic e¡ects of di¡erent
fatty acid species are not restricted to the non-L-cells present
in islets, since the current studies were undertaken with a
clonal L-cell line.
The studies have revealed that, in order to promote cell
death, L-cells must be exposed to saturated fatty acids whose
acyl chain is at least 16 carbon atoms in length (e.g. palmitate,
C16:0). Shorter-chain molecules (such as myristate (C14:0)
and octanoate (C8:0)) were well tolerated by the cells, even
when present at concentrations in the mM range. This is sig-
ni¢cant since palmitate is the most abundant circulating fatty
acid in vivo [32] and suggests that this molecule could mediate
an increase in L-cell death under conditions when FFA levels
are elevated (e.g. during the progression towards type 2 dia-
betes). In drawing this conclusion it is important to emphasise
that we have not directly determined the free concentrations
of fatty acid generated under our experimental conditions, nor
have we ascertained whether cellular lipid pools are di¡eren-
tially a¡ected by saturated or unsaturated fatty acids. Never-
theless, the fatty acids were complexed to albumin at ratios
that can be expected to yield free fatty acid concentrations
that lie within the physiological (nM) range [18,25].
The presence of one double bond in the hydrocarbon chain
of a C16 or C18 fatty acid (to yield palmitoleate (C16:1) and
oleate (C18:1) respectively) was su⁄cient to markedly atten-
uate the cytotoxic potential suggesting that L-cell apoptosis is
initiated in a highly selective manner by only a small subset of
fatty acids. Even more strikingly, it was observed that palmi-
toleate and oleate were able to attenuate the cytotoxic actions
of palmitate (and stearate) suggesting that the unsaturated
molecules exert a profoundly anti-apoptotic response in
L-cells. These data are consistent with recent results in isolated
human islets [20,23]. In an important extension of these stud-
ies, it was established that the e¡ects of mono-unsaturated
fatty acids were not restricted to inhibition of palmitate (or
stearate)-induced toxicity since similar inhibition of cell death
was also evident when either serum withdrawal or exposure to
cytokines was used as the pro-apoptotic stimulus. As the
underlying mechanism responsible for initiation of apoptosis
in each of these circumstances is di¡erent, this implies that
mono-unsaturated fatty acids must in£uence a distal compo-
nent of the apoptotic pathway that is common to multiple
stimuli.
The mechanisms of cytokine-induced apoptosis are argu-
ably the best understood in pancreatic L-cells since it is widely
accepted that treatment of cells with IL-1L and IFNQ leads to
the induction of iNOS and, thereby, to an elevation of NO
[2,3]. This in turn promotes cell death by virtue of increased
protein and DNA nitrosylation, inhibition of key metabolic
enzymes and increased cGMP generation [3^5,33]. Ultimately,
these culminate in the opening of the mitochondrial perme-
Fig. 4. E¡ects of fatty acids and cytokines on nitrite formation and
cell death in BRIN-BD11 cells. A: Cells were left untreated or were
exposed for 24 h to cytokines [IL-1L (2 pg/Wl) plus IFNQ (1 U/Wl)],
palmitoleate (PO; 0.5 mM) or palmitate (Palm; 0.5 mM) as shown.
After this time the medium was sampled and the extent of nitrite
formation measured. *P6 0.001 relative to untreated cells. B: Cells
were left untreated or were exposed for 24 h to cytokines [IL-1L
(2 pg/Wl) plus IFNQ (1 U/Wl)], palmitoleate (PO; 0.5 mM) or palmi-
tate (Palm; 0.5 mM) as shown. After this time the cells were har-
vested and their viability measured. *P6 0.001 relative to untreated
cells ; **P6 0.01 relative to cells exposed to cytokines in the absence
of palmitoleate.
FEBS 28093 16-2-04
H.J. Welters et al./FEBS Letters 560 (2004) 103^108106
ability transition pore, release of cytochrome c and activation
of e¡ector caspases [34]. The present ¢nding that the ability of
palmitoleate to promote L-cell viability was not associated
with any reduction in nitrite formation during incubation
with IL-1L and IFNQ reveals that mono-unsaturates do not
regulate the early steps in this sequence. Moreover, they also
reveal that the potentially ‘toxic’ e¡ects of elevated NO gen-
eration can be antagonised successfully in L-cells, without nec-
essarily down-regulating NO production per se.
It has been reported in some studies that saturated fatty
acids promote an increase in L-cell NO formation [14^16]
suggesting that generation of this radical could represent a
common feature of the mechanisms of action of cytokines
and FFA. However, increased iNOS transcription and NO
production have not always been seen in cells exposed to
saturated fatty acids [17^19] and we were unable to detect
signi¢cant nitrite formation (an index of NO generation) in
the medium of BRIN cells exposed to cytotoxic concentra-
tions of palmitate. Thus, we conclude that the anti-apoptotic
actions of palmitoleate are not mediated by reduced NO for-
mation (in cells incubated either with saturated fatty acids or
with cytokines) and that this molecule intervenes at a more
distal step in the apoptotic pathway.
The mechanism by which serum withdrawal promotes apo-
ptosis probably involves the removal of survival signals re-
quired for the long-term maintenance of viability. Such signals
are principally mediated by a phosphatidylinositol 3-kinase
(PI3K)-dependent mechanism that is attenuated upon removal
of the various growth factors present in serum [35^37]. In
breast cancer cells, oleate has been reported to activate
PI3K [22] suggesting that regulation of this pathway might
represent a target for the pro-apoptotic e¡ects of unsaturated
fatty acids in L-cells. Indeed, such a mechanism might also
explain their ability to antagonise the pro-apoptotic e¡ects of
cytokines and saturated fatty acids. However, we have ob-
served that treatment of BRIN cells with either of two
PI3K inhibitors (wortmannin or LY294002) failed to reduce
the protective e¡ects of palmitoleate on apoptosis (H.J. Wel-
ters, C. Boyle and N.G. Morgan, unpublished observations).
Thus, it is unlikely that the PI3K pathway is a principal target
for the anti-apoptotic actions of mono-unsaturates in L-cells.
Therefore, it appears that mono-unsaturates regulate apo-
ptosis by acting at a relatively distal step, which lies at, or
beyond, the point of convergence of a variety of di¡erent
pathways involved in promoting apoptosis. In support of
this, we found that palmitoleate was still e¡ective as an in-
hibitor of palmitate-induced cell death even when the unsat-
urated molecule was introduced as late as 6 h after initial
exposure of cells to palmitate. Since the activation of apopto-
sis by palmitate is initiated within the ¢rst 2^4 h of palmitate
exposure and changes in the transcription of early response
genes are already complete by this time [38], this con¢rms that
palmitoleate regulates a more distal step in the pathway.
The precise site of action of palmitoleate remains to be
identi¢ed but it may be signi¢cant that mono-unsaturated
fatty acids have recently been shown to attenuate the release
of cytochrome c from L-cell mitochondria [21]. This represents
a critical distal step in the apoptotic pathway and requires the
earlier release of cytochrome c from binding sites located on
the inner mitochondrial membrane. It is not known how this
initial displacement of cytochrome c occurs but recent evi-
dence implies that it may involve a change in the availability
of cardiolipin [26,27]. Cardiolipin is a unique phospholipid
that carries four acyl groups that are normally derived from
unsaturated fatty acids. Thus, incubation of cells with mono-
unsaturates will promote cardiolipin synthesis and, as a result,
may inhibit cytochrome c release. This mechanism would ex-
plain why the non-toxic lipids myristate and octanoate failed
to protect against the cytotoxicity of longer-chain saturated
molecules, since neither would be expected to maintain car-
diolipin levels as e¡ectively as the mono-unsaturates. Regula-
tion of cardiolipin synthesis could also account for the present
¢nding that low concentrations of palmitoleate signi¢cantly
inhibited cell death induced by a 50-fold greater concentration
of palmitate. This is because the substrate speci¢city of car-
diolipin synthase for unsaturated fatty acids is su⁄ciently high
that even low concentrations would be expected to compete
e¡ectively with saturated molecules and thereby promote car-
diolipin synthesis [27]. Thus, changes in cardiolipin availabil-
ity may explain the protective e¡ects of unsaturated fatty
acids and we are currently examining this hypothesis.
Irrespective of the mechanisms involved, the current studies
have revealed that mono-unsaturated fatty acids have the
unique capacity to antagonise apoptosis induced by the acti-
vation of several di¡erent pathways in pancreatic L-cells.
Since these pathways are regulated by agents implicated in
the loss of pancreatic L-cells in both type 1 (cytokines) and
type 2 (saturated fatty acids) diabetes, this suggests that
mono-unsaturated fatty acids may have the potential to re-
duce the rate of L-cell loss associated with these conditions.
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